Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Mercurio

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Frontiers in Cardiovascular Medicine|May 16, 2022
Extracellular Nucleophosmin Is Increased in Psoriasis and Correlates With the Determinants of Cardiovascular DiseasesMarco D'Agostino, Sara Beji, Sara Sileno, et al.
Aging|April 18, 2020
Intracellular Insulin-like growth factor binding protein 2 (IGFBP2) contributes to the senescence of keratinocytes in psoriasis by stabilizing cytoplasmic p21Laura Mercurio, Daniela Lulli, Francesca Mascia, et al.
Cell Death & Disease|November 1, 2018
IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatmentLaura Mercurio, Martina Morelli, Claudia Scarponi, et al.
The Journal of Pathology. Clinical Research|October 3, 2019
Paradoxical psoriasis induced by TNF-α blockade shows immunological features typical of the early phase of psoriasis developmentLuca Fania, Martina Morelli, Claudia Scarponi, et al.
Frontiers in Immunology|April 27, 2026
CXCL13 as a simple and promising blood biomarker for differentiating Sézary syndrome from mycosis fungoides and other confounding chronic inflammatory skin diseasesGiulia Salvatore, Ylenia Aura Minafò, Nicoletta Croce, et al.
Life (Basel, Switzerland)|November 27, 2025
Anti-IL-17 and Anti-IL-23 Therapies Modulate Serum Biomarkers of Intestinal Dysbiosis and Oxidative Stress Linked to Cardiovascular Risk in Patients with PsoriasisGiuseppe Annunziata, Emanuele Scala, Laura Mercurio, et al.
The British Journal of Dermatology|April 17, 2026
The nerve growth factor receptor p75NTR interacts with toll like receptor 4 and the alarmins high mobility group box-1 and nucleophosmin: a novel inflammatory mechanism in psoriasisSara Sileno, Marco D'Agostino, Luciapia Farina, et al.
Human Molecular Genetics|September 11, 2021
Hyperactive HRAS dysregulates energetic metabolism in fibroblasts from patients with Costello syndrome via enhanced production of reactive oxidizing speciesGiovanna Carpentieri, Chiara Leoni, Donatella Pietraforte, et al.
Frontiers in Immunology|July 31, 2025
Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patientsRoberta Belli, Anna Dattolo, Francesca Sampogna, et al.
Frontiers in Immunology|April 27, 2026
Genetic profiling of patients with atopic dermatitis reveals immune and skin barrier variants associated with generalized eczema and optimal response to Dupilumab therapyMartina Morelli, Giovanni Luca Scaglione, Anna Dattolo, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Frontiers in Cardiovascular Medicine|May 16, 2022
Extracellular Nucleophosmin Is Increased in Psoriasis and Correlates With the Determinants of Cardiovascular DiseasesMarco D'Agostino, Sara Beji, Sara Sileno, et al.
Aging|April 18, 2020
Intracellular Insulin-like growth factor binding protein 2 (IGFBP2) contributes to the senescence of keratinocytes in psoriasis by stabilizing cytoplasmic p21Laura Mercurio, Daniela Lulli, Francesca Mascia, et al.
Cell Death & Disease|November 1, 2018
IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatmentLaura Mercurio, Martina Morelli, Claudia Scarponi, et al.
The Journal of Pathology. Clinical Research|October 3, 2019
Paradoxical psoriasis induced by TNF-α blockade shows immunological features typical of the early phase of psoriasis developmentLuca Fania, Martina Morelli, Claudia Scarponi, et al.
Frontiers in Immunology|April 27, 2026
CXCL13 as a simple and promising blood biomarker for differentiating Sézary syndrome from mycosis fungoides and other confounding chronic inflammatory skin diseasesGiulia Salvatore, Ylenia Aura Minafò, Nicoletta Croce, et al.
Life (Basel, Switzerland)|November 27, 2025
Anti-IL-17 and Anti-IL-23 Therapies Modulate Serum Biomarkers of Intestinal Dysbiosis and Oxidative Stress Linked to Cardiovascular Risk in Patients with PsoriasisGiuseppe Annunziata, Emanuele Scala, Laura Mercurio, et al.
The British Journal of Dermatology|April 17, 2026
The nerve growth factor receptor p75NTR interacts with toll like receptor 4 and the alarmins high mobility group box-1 and nucleophosmin: a novel inflammatory mechanism in psoriasisSara Sileno, Marco D'Agostino, Luciapia Farina, et al.
Human Molecular Genetics|September 11, 2021
Hyperactive HRAS dysregulates energetic metabolism in fibroblasts from patients with Costello syndrome via enhanced production of reactive oxidizing speciesGiovanna Carpentieri, Chiara Leoni, Donatella Pietraforte, et al.
Frontiers in Immunology|July 31, 2025
Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patientsRoberta Belli, Anna Dattolo, Francesca Sampogna, et al.
Frontiers in Immunology|April 27, 2026
Genetic profiling of patients with atopic dermatitis reveals immune and skin barrier variants associated with generalized eczema and optimal response to Dupilumab therapyMartina Morelli, Giovanni Luca Scaglione, Anna Dattolo, et al.
Pageof 5